A detailed history of Luts & Greenleigh Group, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Luts & Greenleigh Group, Inc holds 13,869 shares of ABBV stock, worth $3.25 Million. This represents 2.88% of its overall portfolio holdings.

Number of Shares
13,869
Previous 13,917 0.34%
Holding current value
$3.25 Million
Previous $2.58 Billion 24.31%
% of portfolio
2.88%
Previous 2.48%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$184.85 - $231.54 $8,872 - $11,113
-48 Reduced 0.34%
13,869 $3.21 Billion
Q2 2025

Jul 11, 2025

SELL
$170.16 - $206.27 $15,144 - $18,358
-89 Reduced 0.64%
13,917 $2.58 Billion
Q1 2025

May 14, 2025

BUY
$169.2 - $216.66 $37,562 - $48,098
222 Added 1.61%
14,006 $2.93 Billion
Q4 2024

Jan 17, 2025

BUY
$164.99 - $203.87 $4,454 - $5,504
27 Added 0.2%
13,784 $2.45 Billion
Q3 2024

Oct 15, 2024

BUY
$163.84 - $199.33 $21,463 - $26,112
131 Added 0.96%
13,757 $2.72 Billion
Q2 2024

Aug 09, 2024

BUY
$154.79 - $180.76 $11,144 - $13,014
72 Added 0.53%
13,626 $2.34 Billion
Q4 2023

Jan 29, 2024

SELL
$137.6 - $154.97 $963 - $1,084
-7 Reduced 0.05%
13,554 $2.1 Billion
Q3 2023

Nov 01, 2023

SELL
$133.59 - $154.65 $7,080 - $8,196
-53 Reduced 0.39%
13,561 $2.02 Billion
Q2 2023

Jul 17, 2023

SELL
$132.51 - $164.9 $11,660 - $14,511
-88 Reduced 0.64%
13,614 $1.83 Billion
Q1 2023

Apr 13, 2023

SELL
$144.61 - $166.54 $37,743 - $43,466
-261 Reduced 1.87%
13,702 $2.18 Billion
Q4 2022

Mar 30, 2023

BUY
$138.31 - $165.87 $1.93 Million - $2.32 Million
13,963 New
13,963 $2.26 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Luts & Greenleigh Group, Inc Portfolio

Follow Luts & Greenleigh Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Luts & Greenleigh Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Luts & Greenleigh Group, Inc with notifications on news.